Oncology Research and Treatment最新文献

筛选
英文 中文
Evaluating the Impact of Age and G8 Assessment on Definitive Treatment Strategies in Elderly Patients with Local Advanced Esophageal Carcinoma. 评估年龄和 G8 评估对局部晚期食管癌老年患者确定性治疗策略的影响
IF 2 4区 医学
Oncology Research and Treatment Pub Date : 2024-10-16 DOI: 10.1159/000542017
Berna Akkus Yildirim, Sedef Gokhan Acikgoz, Mustafa Halil Akboru, Emre Uysal, Baver Tütün, Necla Gurdal, Yilmaz Tezcan
{"title":"Evaluating the Impact of Age and G8 Assessment on Definitive Treatment Strategies in Elderly Patients with Local Advanced Esophageal Carcinoma.","authors":"Berna Akkus Yildirim, Sedef Gokhan Acikgoz, Mustafa Halil Akboru, Emre Uysal, Baver Tütün, Necla Gurdal, Yilmaz Tezcan","doi":"10.1159/000542017","DOIUrl":"https://doi.org/10.1159/000542017","url":null,"abstract":"<p><strong>Introduction: </strong>While chemoradiotherapy (CRT) is commonly employed as a curative approach for esophageal cancer, administering standard CRT to elderly patients often presents challenges in practical settings. The objective of this study was to compare treatment tolerance and survival outcomes between younger and elderly patients (aged ≥65 years) diagnosed with locally advanced esophageal cancer receiving curative-intent treatment. Additionally, it aims to assess the impact of the Geriatric 8 Health Status Screening Tool (G8 score) on treatment decisions in elderly patients.</p><p><strong>Methods: </strong>Ninety-seven patients treated with neoadjuvant or definitive CRT for locally advanced esophageal cancer were retrospectively evaluated at two centers from 2013 to 2023. We divided the patients by age (&lt;65 and ≥65 years) and assessed their demographic, clinical, and treatment data, including pre- and post-treatment G8 scores. Radiotherapy (RT) was administered at a median dose of 50.4 Gy (45-66 Gy). Planned concurrent chemotherapy was completed in 73 (75.3%) of the patients.</p><p><strong>Results: </strong>In the comparative study of 97 esophageal cancer patients, 48 geriatric (aged ≥65 years) and 49 younger individuals were followed up for a median of 20 and 21 months respectively. No significant statistical differences were noted between the groups concerning baseline and treatment characteristics. Surgical intervention rates were comparable, with 22.9% of geriatric and 36.7% of young patients undergoing surgery (p=0.184). There were no significant differences in pathological complete response, local recurrence, distant metastasis, progression, or death rates. The median progression-free survival (PFS) for geriatric and younger patients was 31 months (95% CI, 13.6-48.4) and 19 months (95% CI, 0-39.4), respectively (p=0.832). The median overall survival (OS) was 38 months (95% CI, 23.8-52.2) in geriatric patients, while it was not reached in younger patients (p=0.745). There was no significant difference between the two groups. The pretreatment and posttreatment G8 values of the geriatric patients were 9.25 (6-13.5) and 9.5 (6-14), respectively. Patients with increased G8 scores were found to have significantly higher PFS (median 85 mo vs. 11 mo, p=0.001) and OS (median 85 mo vs. 14 mo, p=0.001) compared to those with unchanged or decreased G8 scores.</p><p><strong>Conclusion: </strong>Age alone should not be the determining factor in the treatment decision of elderly patients diagnosed with locally advanced esophageal cancer. Moreover, CRT could be safely performed even in patients with low G8 scores, and although the G8 score may not directly influence treatment decision, its enhancement during the treatment process holds significant prognostic value.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. 全面回顾接受酪氨酸激酶抑制剂治疗的非小细胞肺癌的表皮生长因子受体突变情况。
IF 2 4区 医学
Oncology Research and Treatment Pub Date : 2024-10-01 DOI: 10.1159/000541520
Linmiao Zeng, Yiqun Dai, Yuting Liu, Bin Song, Hui Lin, Jianhong Xiao
{"title":"A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.","authors":"Linmiao Zeng, Yiqun Dai, Yuting Liu, Bin Song, Hui Lin, Jianhong Xiao","doi":"10.1159/000541520","DOIUrl":"10.1159/000541520","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is a major contributor to cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are currently viewed as the established first-line therapy for patients with advanced NSCLC with EGFR mutations.</p><p><strong>Summary: </strong>The potential predictive value of the quantitative abundance of epidermal growth factor receptor (EGFR) mutations in the treatment of NSCLC is widely recognized and regarded as a significant indicator. The definition of mutation abundance in the EGFR gene in most current studies is mainly calculated based on the ratio of mutation to wild-type gene copy number or based on the ratio of allele number; for example, variant allele frequency is the ratio of the number of mutant alleles to the total number of alleles at a particular locus. Results of the included primary studies are as follows. (1) Significant association between EGFR mutation abundance and progression-free survival (PFS): median PFS was significantly longer in the high abundance group (11.0 months, 95% CI: 9.7-12.3 months) than in the low abundance group (5.3 months, 95% CI: 3.6-7.0 months) in the study by Liu et al. High mutation abundance (HR: 0.77, 95% CI: 0.66-0.82, p = 0.037) was an independent prognostic determinant of PFS in the study by Wang et al. Among patients receiving EGFR-TKI as first-line therapy, the median PFS was significantly longer in the high mutation abundance group than in the low mutation abundance group (12.7 months vs. 8.7 months, p = 0.002). EGFR mutation abundance ≥30% was an independent risk factor for PFS (HR: 1.64, 95% CI: 1.17-2.31). (2) Significant association between EGFR mutation abundance and overall survival (OS): the median OS in the high abundance group in the study by Liu et al. was 20.9 months (95% CI: 18.3-23.5 months), while that in the low abundance group was 13.0 months (95% CI: 10.0 months) (95% CI: 10.3-15.7 months); longer OS was independently associated with high mutation abundance (HR: 0.62, 95% CI: 0.50-0.79, p = 0.027).</p><p><strong>Key messages: </strong>The objective of this article was to conduct a comprehensive examination and analysis of the association between the abundance of EGFR mutations in NSCLC and the effectiveness of treatment with TKIs while also considering the development of drug resistance.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EGFR-TKI combined with radiotherapy in 105 patients of lung adenocarcinoma with brain metastasis: a retrospective study of prognostic factors analysis. 表皮生长因子受体-TKI联合放疗治疗105例脑转移肺腺癌患者:预后因素分析回顾性研究。
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-09-18 DOI: 10.1159/000541494
Wenjuan Yu,Yuan Xing,Xiao Song,Tian Li,Mi Zhang
{"title":"EGFR-TKI combined with radiotherapy in 105 patients of lung adenocarcinoma with brain metastasis: a retrospective study of prognostic factors analysis.","authors":"Wenjuan Yu,Yuan Xing,Xiao Song,Tian Li,Mi Zhang","doi":"10.1159/000541494","DOIUrl":"https://doi.org/10.1159/000541494","url":null,"abstract":"INTRODUCTIONThis study aimed to retrospectively analyze the response and prognosis factors for patients of lung adenocarcinoma with brain metastasis and epidermal growth factor receptor (EGFR) mutation, who were treated by EGFR-tyrosine kinase inhibitor (TKI) combined with brain radiotherapy (RT).METHODSFrom Jan 2021 to Jan 2024, the clinicopathological data of lung adenocarcinoma patients were collected from the First Affiliated Hospital of Hebei North University. SPSS version 26.0 statistical software was used for statistical analysis. P &lt; 0.05 was determined to be statistically significant.RESULTS105 patients were included. The 1, 2, 3-year overall survival (OS) rate was 82.9%, 61.2%, and 33.7%, respectively. 1, 2 ,3-year progression-free survival 1 (PFS1) rate was 62.7%, 36.6%, 22.1%. 1,2,3-year PFS2 rate was 80.8%, 54.6%, and 31.4%. The median OS, PFS1 and PFS2 was 29.8, 18.0 and 28.1 months, respectively. The COX multivariate analysis showed that gene mutation status and brain radiation dose were independent prognostic factors for OS; Gene mutation status, brain radiation dose, and response evaluation to initial treatment (response evaluation) are independent prognostic factors for PFS1; Clinical stage, gene mutation status, brain radiation dose, and response evaluation are independent prognostic factors for PFS2.CONCLUSIONTKI combined with brain radiotherapy is effective on lung adenocarcinoma patients with EGFR mutation and brain metastasis. Patients with 19 Del or 21 L858R mutation and brain radiation doses ≥ 40 Gy have longer OS, PFS1, and PFS2, and complete remission (CR) + partial remission (PR) is associated with longer PFS1 and PFS2, Patients in stage IVA have longer PFS2.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EGFR plus MET targeted therapies for overcoming treatment resistance in EGFR mutant NSCLC. A Case Report. 表皮生长因子受体(EGFR)加 MET 靶向疗法用于克服表皮生长因子受体突变 NSCLC 的耐药性。病例报告。
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-09-18 DOI: 10.1159/000541496
Maria F Martínez-Hernandez,Luis Lara-Mejía,Carlos Izquierdo-Tolosa,Luis Cabrera-Miranda,Oscar Arrieta
{"title":"EGFR plus MET targeted therapies for overcoming treatment resistance in EGFR mutant NSCLC. A Case Report.","authors":"Maria F Martínez-Hernandez,Luis Lara-Mejía,Carlos Izquierdo-Tolosa,Luis Cabrera-Miranda,Oscar Arrieta","doi":"10.1159/000541496","DOIUrl":"https://doi.org/10.1159/000541496","url":null,"abstract":"INTRODUCTIONOncogenic-addicted non-small cell lung cancer (NSCLC) has emerged as the most prevalent form of lung cancer, presenting a dynamic landscape in treatment modalities. Among these, epidermal growth factor receptor (EGFR)-mutant NSCLC remains the predominant oncogenic mutation, particularly prevalent in regions such as Asia and Latin America.CASE PRESENTATIONThis case study highlights the experience of a woman diagnosed with EGFR-sensitive (del exon 19) mutant NSCLC who demonstrated an extended duration of response (DOR) to third-generation EGFR-TKI therapy. Upon disease progression, detection of MET gene amplification prompted the addition of a selective MET inhibitor to the existing EGFR-TKI regimen, resulting in a complete response for the patient.DISCUSSION/CONCLUSIONThe molecular heterogeneity of this condition has significantly increased in complexity over recent years, marked by the identification of baseline co-alterations and development of a broad spectrum of resistance mechanisms post-EGFR tyrosine kinase inhibitor (TKI) therapy. This complexity poses a substantial challenge to clinicians. Despite the rapid advancement of targeted therapies and the implementation of treatment escalation through combination strategies, there remains an ongoing debate regarding which patients would benefit most from combination therapies, both in the initial treatment phase and in the setting of disease progression, particularly when off-target resistance mechanisms or co-alterations are identified.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines: onkopedia - what´s new? Locally advanced rectal cancer. 指南:百科全书 - 新内容?局部晚期直肠癌。
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-09-17 DOI: 10.1159/000541376
Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann
{"title":"Guidelines: onkopedia - what´s new? Locally advanced rectal cancer.","authors":"Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann","doi":"10.1159/000541376","DOIUrl":"https://doi.org/10.1159/000541376","url":null,"abstract":"This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian and Swiss onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy (TNT) for rectal cancers with high risk features, (ii) treatment with neoadjuvant chemotherapy for patient with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high /dMMR rectal cancer as well as (iv) intended organ preservation as a treatment goal. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options and risks of individual treatment approaches.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. 紫杉醇/Ramucirumab与紫杉醇在晚期食管鳞癌二线治疗中的对比:随机 II 期 IKF-AIO-RAMOS 试验。
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-09-09 DOI: 10.1159/000541174
Magdalena K Scheck,Thorsten O Goetze,Thomas J Ettrich,Harald Schmalenberg,Michael Clemens,Rolf Mahlberg,Steffen Heeg,Stephan Kanzler,Gunnar Hapke,Peter Thuss-Patience,Angelika Kestler,Anne Treschl,Stefan Heidel,Moritz Schiemer,Disorn Sookthai,Sabine Junge,Claudia Pauligk,Salah-Eddin Al-Batran,Sylvie Lorenzen
{"title":"Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.","authors":"Magdalena K Scheck,Thorsten O Goetze,Thomas J Ettrich,Harald Schmalenberg,Michael Clemens,Rolf Mahlberg,Steffen Heeg,Stephan Kanzler,Gunnar Hapke,Peter Thuss-Patience,Angelika Kestler,Anne Treschl,Stefan Heidel,Moritz Schiemer,Disorn Sookthai,Sabine Junge,Claudia Pauligk,Salah-Eddin Al-Batran,Sylvie Lorenzen","doi":"10.1159/000541174","DOIUrl":"https://doi.org/10.1159/000541174","url":null,"abstract":"INTRODUCTIONIn squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line treatment in metastatic esophagogastric adenocarcinoma. We assessed safety and efficacy of ramucirumab/paclitaxel for ESCC.METHODSThis prospective, randomized, open-label, multicenter, phase II trial evaluated paclitaxel (80 mg/m2 d1, 8, 15) plus ramucirumab (8 mg/kg d1, 15) (investigational arm A) vs. paclitaxel alone (80 mg/m2 d1, 8, 15) (standard arm B), both q4w, in advanced/metastatic ESCC refractory or intolerant to fluoropyrimidine and platinum-based drugs. Primary endpoint was overall survival (OS) rate at 6 months.RESULTSFrom 3/2019 to 4/2021, 21/186 planned patients were included (arm A 11 pts; arm B 10 pts) in 9 German centres. Due to slow accrual, the study was terminated prematurely. OS at 6 months was 72.7% for ramucirumab/paclitaxel and 50.0% for paclitaxel. The study design did not allow statistical comparison of the arms. PFS (3.8 vs. 3.5 months), OS (12.1 vs. 9.2 months), ORR (18.2% vs. 20.0%) and DCR (54.5% vs. 60.0%) were comparable in both arms. Most common treatment related adverse events (TRAEs) in arm A were leucopenia (54.5%), fatigue (27.3%) and peripheral sensory neuropathy (18.2%). 27.3% in arm A and 50.0% in arm B had TRAEs ≥ grade 3.CONCLUSIONRamucirumab/paclitaxel shows an acceptable tolerability and numerically improved OS at 6 months. Due to the small number of patients the current trial must be considered exploratory and more data are needed in this indication.REGISTRATIONClinicalTrials.gov, NCT03762564. IKF-s627 RAMOS Study.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142224928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction of a New Satellite Model for Participation in Clinical Trials in a Consortial Comprehensive Cancer Center with Four University Hospitals in Germany. 在德国一家由四所大学医院组成的联合综合癌症中心,引入了一种参与临床试验的新卫星模式。
IF 2 4区 医学
Oncology Research and Treatment Pub Date : 2024-08-21 DOI: 10.1159/000541038
Johanna Teloh-Benger, Susanne Isfort, Norbert Gattermann, Ingo G H Schmidt-Wolf, Martina Crysandt, Angelika Kötting, Annett Falkenhahn, Olivia Hardebeck, Kristoffer Lenssen, Alexander Werz, Alexandra Krüger, Thomas Zander
{"title":"Introduction of a New Satellite Model for Participation in Clinical Trials in a Consortial Comprehensive Cancer Center with Four University Hospitals in Germany.","authors":"Johanna Teloh-Benger, Susanne Isfort, Norbert Gattermann, Ingo G H Schmidt-Wolf, Martina Crysandt, Angelika Kötting, Annett Falkenhahn, Olivia Hardebeck, Kristoffer Lenssen, Alexander Werz, Alexandra Krüger, Thomas Zander","doi":"10.1159/000541038","DOIUrl":"10.1159/000541038","url":null,"abstract":"<p><strong>Introduction: </strong>The trend toward personalized medicine leads to very small study cohorts for clinical trials, which makes it difficult to recruit patients in a single study center. On the other hand, the administrative effort required to initiate a clinical trial is very high. As a result, Germany runs the risk of falling behind other countries as a trial location. For this reason, the Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) has been working on the challenge of a new satellite model in which the main trial center is the only one to conclude a trial center contract with the sponsor and also handles all formalities with it. The remaining sites constitute the satellites. In contrast to former satellite models, the entire study-related interventions are carried out at each site in the present model.</p><p><strong>Methods: </strong>In order to evaluate the approvability of the model, contact was made with both higher federal authorities and the responsible inspectorate, and none of them declared themselves responsible for a possible basic approval. The four ethics committees contacted agreed to the model subject to certain framework conditions. In addition, the model was validated by the preparation of several legal opinions on various issues (medical, labor, antitrust law).</p><p><strong>Conclusion: </strong>Study participation close to home is a decisive advantage for multimorbid patients. As up to four locations form a trial site in the model, a large catchment area can be covered with reduced administrative costs. The satellite model developed is intended to give patients broader access to medical innovations in cancer therapy.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review. 阴茎转移的立体定向放射治疗:病例报告和系统文献综述。
IF 2 4区 医学
Oncology Research and Treatment Pub Date : 2024-05-18 DOI: 10.1159/000539275
Antonio Piras, Andrea D'Aviero, Antonella Sanfratello, Luca Boldrini, Gianfranco Pernice, Massimiliano Spada, Gianluca Gaudio, Mirko Pinelli, Giuseppe Salamone, Vittorio Gebbia, Nino Dispensa, Gabriele Tulone, Riccardo Laudicella, Albert Comelli, Domenico Di Raimondo, Antonino Tuttolomondo, Tommaso Angileri, Antonino Daidone
{"title":"Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review.","authors":"Antonio Piras, Andrea D'Aviero, Antonella Sanfratello, Luca Boldrini, Gianfranco Pernice, Massimiliano Spada, Gianluca Gaudio, Mirko Pinelli, Giuseppe Salamone, Vittorio Gebbia, Nino Dispensa, Gabriele Tulone, Riccardo Laudicella, Albert Comelli, Domenico Di Raimondo, Antonino Tuttolomondo, Tommaso Angileri, Antonino Daidone","doi":"10.1159/000539275","DOIUrl":"10.1159/000539275","url":null,"abstract":"<p><strong>Introduction: </strong>Penile metastases (PMs) are a rare clinical presentation mainly related to advanced stages of disease. Considering the low incidence, an optimal treatment approach has not yet been defined; surgery, chemotherapy, and radiotherapy (RT) are different options used in the vast majority with palliative intent. The advances in modern RT can represent an innovative tool in PM management and a curative option. This paper aimed to report the case of a PM patient treated with stereotactic body radiotherapy (SBRT) and perform a systematic literature review of current evidence on the RT approach to PM.</p><p><strong>Case presentation: </strong>We reported the case of an 80-year-old patient with PM from primary bladder cancer. Following the surgical approach for the primary tumor, evidence of PM was shown, and the patient was admitted to SBRT treatment on PM after an adjuvant RT course on the pelvis. A 25 Gy in 5-fraction SBRT treatment was performed, and a complete clinical response was shown at the first follow-up. A PubMed/MEDLINE and Embase systematic review was carried out. The search strategy terms were [(\"penile metastasis\"/exp OR \"penile metastasis\" OR (penile AND (\"metastasis\"/exp OR metastasis))) AND (\"radiotherapy\"/exp OR radiotherapy)] and only original articles up to October 24, 2023 were considered.</p><p><strong>Conclusion: </strong>A total of 174 studies were obtained using the previously mentioned search strategy, and the analysis was performed on 15 papers obtained following the complete selection process. All reported evidence was focused on the palliative approach of PM, showing good results in terms of symptom control. The potential role of modern RT in the management of PM has yet to be defined. The reported case showed the feasibility and the clinical impact of SBRT in PM treatment.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between metabolic reprogramming and immune regulation in digestive tract tumors. 消化道肿瘤的代谢重编程与免疫调节之间的关系
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-04-18 DOI: 10.1159/000538659
Jiafeng Liu, Tianxiao Wang, Wenxin Zhang, Yuxin Huang, Xinhai Wang, Qunyi Li
{"title":"Association between metabolic reprogramming and immune regulation in digestive tract tumors.","authors":"Jiafeng Liu, Tianxiao Wang, Wenxin Zhang, Yuxin Huang, Xinhai Wang, Qunyi Li","doi":"10.1159/000538659","DOIUrl":"https://doi.org/10.1159/000538659","url":null,"abstract":"BACKGROUND\u0000The cancers of the digestive tract, including colorectal cancer (CRC), gastric cancer (GC) and Esophageal cancer (ESCA), are part of the most common cancers as well as one of the most important leading causes of cancer death worldwide.\u0000\u0000\u0000SUMMARY\u0000Despite the emergence of immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1) in the past decade, offering renewed optimism in cancer treatment, only a fraction of patients derive benefit from these therapies. This limited efficacy may stem from tumor heterogeneity and the impact of metabolic reprogramming on both tumor cells and immune cells within the tumor microenvironment (TME). The metabolic reprogramming of glucose, lipids, amino acids, and other nutrients represents a pivotal hallmark of cancer, serving to generate energy, reducing-equivalent and biological macromolecule, thereby fostering tumor proliferation and invasion. Significantly, the metabolic reprogramming of tumor cells can orchestrate changes within the TME, rendering patients unresponsive to immunotherapy.\u0000\u0000\u0000KEY MESSAGES\u0000In this review, we predominantly encapsulate recent strides on metabolic reprogramming among digestive tract cancer, especially CRC, in the TME with a focus on how these alterations influence antitumor immunity. Additionally, we deliberate on potential strategies to address these abnormities in metabolic pathways and the viability of combined therapy within the realm of anticancer immunotherapy.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140689791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastases affecting cranial nervous structures in male breast cancer: Two cases report. 影响颅神经结构的男性乳腺癌转移:两例报告。
IF 2.4 4区 医学
Oncology Research and Treatment Pub Date : 2024-04-18 DOI: 10.1159/000538933
Andrea Valera-Barrero, Jorge Madera-Fernández, Vicente González-Quintanilla, M. J. Sedano-Tous, Francisco Martínez Dubarbie
{"title":"Metastases affecting cranial nervous structures in male breast cancer: Two cases report.","authors":"Andrea Valera-Barrero, Jorge Madera-Fernández, Vicente González-Quintanilla, M. J. Sedano-Tous, Francisco Martínez Dubarbie","doi":"10.1159/000538933","DOIUrl":"https://doi.org/10.1159/000538933","url":null,"abstract":"INTRODUCTION\u0000Breast cancer in males is a very rare entity, and survival is mainly influenced by the stage at diagnosis. The lack of early detection tools in men results in a diagnostic delay of about 5-10 years and a higher percentage of metastatic disease at diagnosis. However, the characteristics of head metastases are not well defined.\u0000\u0000\u0000CASE REPORTS\u0000We present two cases of male breast cancer with metastases affecting cranial nervous structures and we provide imaging and histologic data. Both were middle-aged patients with ductal-type, HER-2 negative and androgen receptor positive primary tumors.\u0000\u0000\u0000DISCUSSION\u0000Although central nervous system involvement is uncommon, this entity should be considered in middle-aged males with focal neurologic symptoms. More cases would be necessary to better understand the biology of this condition in order to establish an adequate diagnosis and treatment.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140687999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信